NCT00898950View on ClinicalTrials.gov

Effects of Different Doses of Aspirin on Pathophysiological Markers in Type 2 Diabetes

NACompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

July 31, 2006

Study Completion Date

July 31, 2006

Conditions
Diabetes Type 2
Interventions
DRUG

Aspirin

Aspirin 75mgs/day orally for 2 weeks.

DRUG

Aspirin

300mgs/day orally for 2 weeks

DRUG

Aspirin

aspirin 900mgs QID orally for 2 weeks

OTHER

placebo tablet

placebo tablet with lactose and excipients.

Trial Locations (2)

PO1 2DT

School of Pharmacy and Biomedical Sciences, University of Posrtmouth, Portsmouth

PO6 3LY

Diabetes Centre, Queen Alexandra Hospital, Portsmouth Hospitals NHS Trust, Portsmouth

All Listed Sponsors
lead

University of Portsmouth

OTHER

NCT00898950 - Effects of Different Doses of Aspirin on Pathophysiological Markers in Type 2 Diabetes | Biotech Hunter | Biotech Hunter